Podcasts about DRS

Welcome to Protecting Your Nest with Dr. Tony Hampton. John E. Ellis, MD is a retired anesthesiologist. Following years of struggling with weight and metabolic health, Dr. Ellis discovered the power of a low-carb lifestyle—losing excess weight, improving his energy, and reclaiming his vitality. Now he's passionate about sharing what he's learned, blending a physician's eye for evidence with the lived experience of someone who has reshaped his own health. Through speaking, mentoring, and community engagement, Dr. Ellis inspires others to rethink nutrition and take control of their wellbeing.   In this discussion, Drs. Tony and John talk about: (00:00) Intro (03:16) Dr. John's career in medicine and personal health journey (21:38) Cooking and shopping to make a low carb diet sustainable (27:01) Exercise: cardio and resistance training (33:39) Saturated fat (38:41) Why doctors and medical practitioners have been slow to accept the legitimacy of the low carb and keto diets (47:52) The toxic food and movement environments many find themselves in in the USA (54:05) The importance of community and communication on important topics like low carb and keto amongst doctors and other medical professionals (01:01:21) How vegans can get adequate protein (01:08:46) Dr. Tony's NEST and ROPE acronyms   Thank you for listening to Protecting Your Nest. For additional resources and information, please see the links below.   Links:   Dr. John Ellis: X: https://x.com/howilost100lbs Website: https://howilost100lbs.com/ YouTube: https://www.youtube.com/@johnellis2988   Dr. Tony Hampton: Linktree: https://linktr.ee/drtonyhampton Instagram Account: https://www.instagram.com/drtonyhampton/ LinkedIn Account: https://www.linkedin.com/in/drtonyhampton/ Ritmos Negros Podcast: https://podcasts.apple.com/us/podcast/ritmos-negros/id1534043495 Q Med: https://qmedcme.com Symposium for Metabolic Health Lectures: https://www.lowcarbusa.org/smhp-symposiums/san-diego-2022/ How Waking Up Every Day at 4:30 Can Change Your Life: https://www.youtube.com/watch?v=qOEB1Fr0_MM • • Keto Mojo: https://keto-mojo.com/speakers/tony-hampton/

What happens when physical therapy embraces the tools of diagnostic medicine? In this episode, Garrett talks with Drs. Skye Grayson, Malachi Votaw, and Julia Whitehead from NCEPT (Escondido, California) about how they've built one of the most advanced PT practices in the country by combining EMG, ultrasound, and Neubie neuromuscular reeducation. You'll learn about: How objective diagnostics uncover what's really driving movement limitations The difference between structural and neurological dysfunction – and why it matters How Neubie integration accelerates nerve recovery and neuromuscular control Building a hybrid model that blends insurance-based care with cash-based innovation NCEPT's team-driven approach to leadership, mentorship, and excellence This is a look inside the next evolution of physical therapy, where you'll see a clear and inspiring picture of how technology and teamwork converge to create better outcomes and stronger practices.  

Previous Zoo Logic podcast guests, Drs. Bruck, Jaakkola, and Hill conduct original research with cetaceans and each has an extensive scientific publication record. They also have significant experience as journal reviewers. A recent "review" paper was published despite our panel of experts best attempts to adhere to sound scientific norms and the peer review process. After many many hours of analysis of the manuscript and its citations, they urged journal editors to reject publication through their exhaustive written reviews, which are publicly available. The paper's authors, led by a long time critic of marine mammals in human care, held a webinar accusing the zoological industry of trying to censor this publication. Our panel shares their public criticisms of the paper, and the journal that elected to ignore their major concerns, and what such publications do to the process of conducting and communicating science. The paper and the complete reviews can be found here. Animal Care Software

In this rerun episode, Drs. May and Tim revisit one of their most grounded conversations: the real meaning of thankfulness. They explore why gratitude is so hard to maintain in a world that profits from your dissatisfaction, how social media has turned gratitude into a trend, and why Black Friday perfectly exposes the contradiction of the season. They share personal reflections on contentment, the endless pursuit of “better,” and the simple practice of pausing long enough to appreciate what's already in front of you. It's an episode that feels just as relevant today as it did the first time—maybe even more.GET SOCIAL WITH US!

In this episode of Counsel the Word Pastor Keith Palmer talks with Drs. Nicolas and Venessa Ellen about finding grace in grief. You can purchase Dr. Venessa Ellen's new book titled Grace in the Mourning: A Faith-Filled Journey through Grief on her website.

Why is it that women experience stress more intensely than men? Drs. Daina Parent and Annette Schippel discuss the connection between women's hormones and the effects of stress on the female body. Dr. Schippel shares her personal and professional experience navigating the stages of a woman's reproductive journey and how endocrine health plays a significant role in hormone balance. Drs. Parent and Schipple emphasize the importance of working with qualified healthcare providers trained in herbal medicine in order to find the right herbs for each person and symptom picture. Dr. Schippel offers invaluable clinical tools and takeaways to create a strong foundation for any woman to navigate stress management and optimal wellness with nutrition, herbs, lifestyle and more. Dr. Annette Schippel is a chiropractor and a graduate of Logan College of Chiropractic, she brings over 25 years of experience to her work. She owns two thriving family practices that focus on pediatrics, women's health, and clinical nutrition, and she regularly sees patients from across the United States and around the world. Known for her expertise in functional medicine and endocrinology, Dr. Schippel has become a respected educator, author, and speaker. She has written and co-authored numerous clinician manuals and lectures domestically and internationally on topics in nutrition and functional endocrinology.  She has had the privilege of visiting Medi-Herb in Australia for 3 years to receive advanced training in phytotherapy.  She also had the honor to speak on alternative approaches to Metabolic Syndrome at the 2014 International Health Management Forum in Bejing China. Show Summary 2:24 Female hormones and stress sensitivity 4:00 The HPA Axis and the stress response 5:35 The thyroid adrenal connection 7:57 Cortisol, DHEA and the adrenal cortex 9:15 Prolactin, dopamine and high prevalence of autoimmunity in women 11:30 Key differences in male and female hormones: estradiol, testosterone, and DHEA 15:27 Peri- and menopausal hormone shifts 16:33 Adrenal burnout and perimenopause: the resiliency of the stress response affects hormone balance 21:13 Clinical strategies for adrenal support to mitigate perimenopausal symptoms – diet, exercise, sleep, digestion, and mental health 25:42 Herbs for adrenal support and endocrine balance – rehmania, ashwagandha, chaste tree, schizandra and more 29:33 How herbs modulate and synergize with hormones 30:02 Social media trends – perspectives on ashwagandha 33:06 Why guidance from a healthcare provider with herbal knowledge matters – finding the right herbs for each person 35:35 Choosing the right herb – how patient health history and symptom picture inform herbal selection 44:39 Using blood chemistry to inform patient protocols 45:55 Personalizing herbal protocols for different stages of the lifespan 48:38 Nutrients and herbs for libido and vaginal dryness and how adrenal resilience plays a role in these symptoms 50:32 Circulation, sexual health, and blood-flow support 52:53 Improving vasodilation through nitric oxide; whole foods and herbs that support circulation (beets, mountain spinach, red algae, and more) 54:45 Herbs as modulators – herbs won't increase or decrease hormones too much 55:16 The truth about wild yam creams 58:54 The practitioner-patient journey - navigating better health together 1:01:51 Key clinical takeaway for supporting women's health and stress management – how to build a good foundation and never lose sight of what you're trying to build

In this episode of SurgOnc Today, SSO Breast Disease Site Working Group members Drs. David Anderson, Fred Dirbas, and Suzanne Klimberg dive into management of male breast cancer. The speakers discuss unique considerations for this population as well as the similarities and overlap when treating female breast cancer.

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

Waarom dit tijdperk móét instorten volgens Drs. Karen Hamaker-Zondag | The Trueman Show #252   Jaaa, daar is ze weer! Deze week in The Trueman Show: Karen Hamaker-Zondag.    Karen heeft natuurlijk voor de meesten van jullie geen introductie meer nodig. Ze is een vertrouwd gezicht, een vriendin van de show en iemand die de chaos van deze tijd als geen ander kan duiden.   We vonden het hoog tijd voor een update, dus in dit gesprek neemt ze ons mee van de oudste moedergodinnenculturen tot de moderne machtsstructuren die nu voor onze ogen instorten. Volgens haar leven we niet zomaar in onrustige tijden, maar midden in een eindtijd.   We hebben het over de eeuwenlange onderdrukking van yin-waarden, over schaduwwerk, over mannen en vrouwen die hun kracht terugvinden, maar ook over wat er nu geopolitiek en spiritueel onder onze voeten verschuift. En vooral: wat jij zelf te doen hebt in deze overgangstijd.   In deze podcast: Van moedergodinnen tot moderne macht Het oude systeem dat instort, en waarom dat hoopvol is Animus & Anima: onze mannelijke en vrouwelijke kracht Projectie, polarisatie & schaduwwerk EU, NAVO en oude structuren naderen hun einde De nieuwe tijd: lokaal, menselijk, natuurrecht Innerlijk werk als sleutel tot vrijheid   Word Member en bekijk Uncensored op That's The Spirit: https://thatsthespirit.nu/in   Volg ons op: Instagram: / thetruemanshowpodcast Facebook: / thetruemanshowpodcast Telegram: https://t.me/s/jornluka?before=217 X: / TruemanshowNL   Wekelijks op de hoogte blijven van alle afleveringen, updates, boekentips en de blogs van onze gasten? Schrijf je in voor de nieuwsbrief: https://thetruemanshow.com/nieuwsbrief/  Samenwerken met de Trueman Show? Stuur een mail naar partners@thetruemanshow.com   Deze podcast wordt mede mogelijk gemaakt door de volgende sponsoren:   MINDFUL DEALS WEKEN; 17 NOVEMBER -17 DECEMBER Het zijn weer mindful deals weken bij That's The Spirit! Van 17 november tot 17 december krijg je korting op heel veel verschillende producten in de webshop, neem een kijkje op https://shop.thatsthespirit.nu/   AMARAPURE Geef jezelf meer energie en een betere nachtrust met de Roodlicht-Lamp van Amarapure. Bestel via https://amarapure.nl en ontvang 10% korting met code TMS.   MODERN NATIVE Geef je lijf wat het écht nodig heeft met de natuurlijke orgaansupplementen van Modern Native. Gebruik code TMS voor 10% korting: https://modernnative.nl/orgaanmix   AQUALINE FILTER Nederlands kraanwater is van goede kwaliteit, maar bevat nog steeds onzuiverheden zoals chloor, zware metalen en microplastics. De Aqualine waterfilter verwijdert deze schadelijke stoffen en verrijkt het water met essentiële mineralen. Van 22 tot en met 30 november is de Aqualine filter met korting verkrijgbaar in onze webshop: https://shop.thatsthespirit.nu/collections/waterfilters   WOLF OF WASHINGTON Handel mee met politici en profiteer van hun (voor)kennis van de aandelenmarkt. Leden van The Trueman Show krijgen 10% korting via de link https://wolfofwashington.nl/trueman met code TMS   *Dit betreft een commerciële samenwerking, The Trueman Show ontvangt commissie bij aanmelding via de affiliate link” 

In this episode of the ESCRS IME podcast series on simultaneous vision IOLs, Drs. Francesco Carones and Andrea Janeková explore the selection and benefits of these lenses for presbyopia correction. They highlight the importance of tailoring lens choices to each patient's lifestyle and ocular conditions, managing expectations during the adaptation period, and ensuring thorough screening and postoperative care to maximize patient satisfaction. Don't miss this insightful episode and be sure to check out the other expert-led podcasts in the series! Independent medical education supported by Alcon (Gold), J&J (Gold), B+L (Silver), Zeiss (Bronze).

In this episode of the ESCRS IME podcast series on simultaneous vision IOLs, Drs. Andrea Janeková and Francesco Carones discuss how modern imaging and digital tools are transforming intraoperative planning and lens alignment. They highlight the precision and convenience of technologies like swept-source OCT and corneal tomography, yet fewer than half of surgeons use digital visualization consistently. The experts emphasize that proper training and routine use can enhance surgical precision, efficiency, and patient outcomes. Don't miss this insightful episode and be sure to check out the other expert-led podcasts in the series! Independent medical education supported by Alcon (Gold), J&J (Gold), B+L (Silver), Zeiss (Bronze).

In this episode of the ESCRS IME podcast series on simultaneous vision IOLs, Drs. Francesco Carones and Andrea Janeková explain why a healthy ocular surface is essential before cataract refractive surgery. Even mild dry eye can skew keratometry readings and IOL calculations—yet it's often overlooked. Left untreated, dry eye can cause refractive surprises and postoperative dissatisfaction. The experts stress a thorough ocular surface evaluation and show how treating dry eye beforehand ensures more accurate results, better outcomes, and happier patients. Don't miss this insightful episode and be sure to check out the other expert-led podcasts in the series! Independent medical education supported by Alcon (Gold), J&J (Gold), B+L (Silver), Zeiss (Bronze).

On this accredited episode of NP Pulse: The Voice of the Nurse Practitioner®️, expert faculty Drs. Korey Hood and Kathryn Evans-Kreider explore the psychosocial challenges of living with type 1 diabetes, with a focus on how nurse practitioners can support patients experiencing diabetes distress. Faculty discuss practical strategies, such as using brief screening tools, adopting person-first and strengths-based language and tailoring care through shared decision-making. The conversation also highlights the impact of SDOH and the importance of integrating mental health awareness into routine diabetes management. This podcast is part of the Clinical Advantage Bootcamp: Type 1 Diabetes Management Certificate for Nurse Practitioners. Visit the AANP CE Center to view the other modules. A participation code will be provided at the end of the podcast — make sure to write this code down. Once you have listened to the podcast and have the participation code, return to this activity in the AANP CE Center. Click on the "Next Steps" button of the activity and: 1. Enter the participation code that was provided. 2. Complete the posttest. 3. Complete the activity evaluation. This will award your continuing education (CE) credit and certificate of completion. 1.0 CE will be available through Nov. 30, 2027.   Tool link : Diabetes_Billing_and_Coding_Toolkit.pdf   This collaboration between AANP and Danatech, an Association of Diabetes Care and Education Specialists (ADCES) initiative, is made possible thanks to grants from Helmsley Charitable Trust, Abbott and Medtronic.

Formula 1 Chief Commercial Officer Emily Prazer joins The Big Impression to accelerate the motorsport's hold on Americans with year-round content and venue in Las Vegas. Episode TranscriptPlease note, this transcript  may contain minor inconsistencies compared to the episode audio.Damian Fowler (00:00):I'm Damian Fowler.Ilyse Liffreing (00:01):And I'm Ilyse LiffreingDamian Fowler (00:02):And welcome to this edition of The Big Impression.Ilyse Liffreing (00:09):Today we're joined by Emily Prazer, president and CEO of the Las Vegas Grand Prix and the Chief Commercial Officer of Formula One. She's helping transform F1 into one of the fastest growing sports brands in the world, leading strategy partnerships and fan engagement across markets from Miami to Melbourne.Damian Fowler (00:30):Emily's here to talk about the road to the last Vegas Grand Prix on November the 22nd. Now, in its third year, the Vegas Grand Prix turns the strip into a global stage where sport, entertainment and culture collide under the neon lights.Ilyse Liffreing (00:46):I love that. From the 100 day countdown events to new sponsorship models and digital fan experiences, formula One is redefining what a modern sports brand can look like, especially in the U.S. market.Damian Fowler (01:02):In past years, the marketing around Las Vegas, the Grand Prix has felt like a crescendo building over several months. What's been your strategy this year as you build, it's the third year, right? As you build towards those?Emily Prazer (01:14):Yeah, this third year, so I think the difference this year is we've had two years of a foundation to figure out what works and what doesn't work, but equally we've had our building open all year, so prior, well the first year we're obviously building the building for those that dunno, it's called Grand Prix Plaza. It's the length of three NFL fields, so it's not small. It's designed and built to service the Formula One Paddock Club, which is the most high-end hospitality that we offer in Formula One. Underneath that is where the garages are and where the teams hang out, so it's quite a significant building. When we first moved to Vegas, we purchased the 39 acres of land and have invested around $500 million in this infrastructure and so the difference I think is obviously the first year we were building it, the second year we were getting to grips with owning such a significant property in Las Vegas and then moving into the third year of the event, the building's been open all year and we built something called F1 Drive, which is carting.(02:10):We've had a restaurant up there called Fool and Fork, which is Formula One, themed food and beverage as you'd expect. We built an immersive Formula one experience called F1 X and so the marketing's ramped up, but that's because locally we've been able to activate since the day after the race last year all the way through to this year, and obviously how we market is very different depending on what we're trying to do, whether it's selling tickets or whether it's driving foot traffic to the building. It's all the awareness that we need in Las Vegas to continue to grow our fan base.Damian Fowler (02:41):The a hundred day countdown, that's important,Emily Prazer (02:43):Right? That was a big one. We always go big around a hundred days. We did a strip takeover, we made sure people understood that it was a hundred days ago. We did similar for 50 days, so we use those milestones to make sure, obviously Vegas is somewhat a last minute market. Some Grand Prix go on sale and sell out in 90 minutes. We see the most amount of activity from a hundred days through to November.Damian Fowler (03:04):That's very interesting. How do you decide which moments where you target your marketing strategy in that a hundred day buildup?Emily Prazer (03:12):Oh, well, we're very fortunate that the racing continues For those, again, that aren't familiar, formula One is a 24 race calendar, which spans globally, so we typically go big around the big races as you'd expect. We've just come out of Singapore where hopefully people have seen that McLaren won the Constructors Championship. We'll go big again around Austin and Mexico. They're both feeder markets to the Las Vegas Grand Prix and we'll just continue to make sure we've got major announcements, whether it be food and beverage merchandise programming all the way through between now and race day.Ilyse Liffreing (03:42):Now, can you also talk a little bit about the F1 business summits because you're also launching that during race week? Sure. How intentional is the idea of making Vegas not just a race, but a business and cultural destination?Emily Prazer (03:56):Sure. Well, if you look at what Vegas do around other major sports, it's not that we're trying to reinvent the wheel, we're taking learnings from how well the NFL have operated there with the Super Bowl, even around WWE where you see them extend from a one or two day event through to a whole week. We are very fortunate that again, for those that dunno, formula One kicks off on Thursday with free practice, we have qualifying on Friday and then on Saturday is the race. And so we are lucky that we actually have really good opportunity for shoulder programming and so it was a lot of requests coming through from multiple stakeholders saying we'd love to get the ecosystem together and talk about how we've shifted Formula One culturally into something very different. Obviously it's a sport first and foremost, but I think everyone's now seeing the change into more of a lifestyle brand and a proposition around how we're executing with some partners, which I'm sure we'll get to, but I think a lot of it has been around how we kind of talk about that strategy and how we've grown the sport over the last five years.(04:54):So it was very intentional, it's had really great uptake and as you'll see as we get closer to the race, we'll start talking about what we're doing kind of Tuesday, Wednesday all the way through.Damian Fowler (05:04):It was interesting you brought up the mention of partners and the fact that Formula One now transcends the racetrack and I for one say follow some Formula One drivers on Instagram. How do you play into that whole notion now that Formula One is this lifestyle brand and what does that mean when it comes to partnerships?Emily Prazer (05:26):Well, we've been really fortunate that we've, formula One was bought by Liberty Media in 2017 and the handcuffs were taken off per se, where social media was something that didn't really exist in the sport prior to that and the drivers have done a great job and the teams have done a great job of giving us access collectively to the drivers. They're all a lot younger than they have been before, so we've been fortunate enough to help them build their profiles through social, but obviously the pivot came with Drive to Survive. Everyone knows that that was a big leap of faith that Formula One took to be able to give behind the scenes access. It's a complicated sport that had traditionally been kept to a different type of club and we've opened up those floodgates and obviously we're reaping the rewards of that at the moment.(06:10):It hasn't been easy, but ultimately when you have the likes of Netflix wanting to display what we do, hopefully everyone's seen the Formula One movie with Brad Pitt, which is now I think the highest grossing sporting movie of all time and Brad Pitt's highest grossing movie of all time. So that again, is a great explainer if you take that concept, the strategy around all of it has to create this always on dynamic, which isn't just about the 24 race weekends, it's about how to have brand extension through partnerships 24 7, 365 days a year that's come to life through our licensing business, which I can get to and also our sponsorship business, that the thought process was we want to sign less B2B organizations more consumer brands, not because we don't appreciate, we are always going to have a B2B element Formula One lives in that space, especially on the technical side of the sport, but as it talks about how we penetrate the fan base, how we acquire new fans and how we talk to fans differently.(07:06):One of the big pieces of it was, well, how do we show up in every shopping mall, not just in North America, but globally and using the likes of Lego? You would've seen our recent announcement with Tag Hoya. You now go to these shopping malls and you see these different brands actually activating and taking some learnings from how the US sports do it, where everywhere you go you can buy a t-shirt. I think one of my proudest moments was being at the Super Bowl last year in New Orleans and seeing people in the parade wearing Formula one T-shirts.(07:32):I was like, that shows that the strategy is working. In addition to we acknowledge that pricing of Grand Prix is expensive, they're also places you typically have to travel to, and so brand extension through license partners has been really important. We have something called F1 Drive, which we'll be rolling out, which is the carting proposition I mentioned in Vegas we have F1 arcade, which is now opening up and popping up all over North America. We have F1 exhibition, which is a tribute to the history of the sport and we'll keep growing as we want to keep penetrating and explaining to those fansIlyse Liffreing (08:07):Fans. That is really interesting hearing you describe just how different the strategy here is in the US too because F1 is such a global brand. How do you I guess, keep the brand though true to its global roots at the same time as also making it feel like America's race?Emily Prazer (08:25):Definitely not trying to make it feel like America's race. I think taking the learnings of how to speak to the audience we've acquired wherever we go, the benefit of being a global sport is we're global, but in each of those destinations we act very local. So when you're there, you very much know that when you're at the British Grand Prix that you're at Silverstone and there's all of the heritage around it, Monza, there's nothing more special in global sport in my opinion, than seeing the ZI on a Sunday run onto the grid with the Ferrari flags and what have you that you can't take that passion and bottle it up and just pop it into a US race. The US market is different, but if you look at how Miami has identified itself, you for sure know where you are. Same with Austin, where it's Texas and everybody is in cowboy boots and you know that you're in Texas and then Vegas takes it to a different level because we partner with our friends at the L-B-C-V-A and other partners in Vegas to bring that kind of extreme entertainment to life. So yeah, wherever you go, you really do know where you are and that's where I think the local element comes into play.Ilyse Liffreing (09:28):Has anything changed in the sports rights context in order for Formula One to really be able to create more social and organic marketing tied to the event?Emily Prazer (09:41):Yeah, I think it's that we've got the confidence to try different things and have given different types of access. So you'll see obviously that we have lots of short form content. Now we're noticing that this generation of fandom that we're trying to continue to excite wants to look at things slightly differently, whether it be through YouTube or TikTok. I think we're launching our first TikTok store in a couple of weeks, which I never thought we would be in a place to do, but it's a testament to where the sports got to. So I don't think the rights have changed. I think our approach to it has changed where we have the confidence because of the excitement around destinations like Las Vegas to shift our mindset. Like I say, we're not going to do it everywhere. We're going to pick specific places to test it, and Vegas for us for the last three years has served as that test testbed.(10:28):You'll see the collaborations alone that we do in the merchandise space we've not been able to replicate prior and we're proud of it. What we're doing there is giving us the confidence to deliver new partnerships across the sport. American Express is a prime example where they came in as a Vegas only partner, did a year of that, a year later became a regional partner, so they activated across the Americas and then a year after that became a global partner. So it's just showing that we can bring in these more consumer led brands, but also how we've shifted our mindset to be able to deliver against it.Damian Fowler (11:00):That happened very fast. It's kind of amazing. You touched on this a little bit, but the different audiences in the different markets. What have you learned after the first two years of hosting Grand Prix in the United States about American fans specifically?Emily Prazer (11:16):Just that you need to give them variety. They aren't going to come in and behave the same way as a traditional Motorsport fan that has been or has grown up with. The heritage of the British audience is a great example where I mentioned Silverstone goes on sale and sells out. We've had to adjust the product to make sure that we're very much catering to that audience and the programming around it, like we talked about, has been super important. People don't want to come just for one session, but they want the option to come and leave and go to a casino or go to a different show and what have you. So they're looking for all round entertainment, not just coming to watch the Formula One event, which we focus specifically on making sure that we deliver against.Damian Fowler (11:59):One thing that's interesting about Vegas as well is that it's a big draw for tourism globally as well and people fly in. So maybe that fan base is also kind of a mix of international and local.Emily Prazer (12:11):Yeah, well interestingly, we've seen the majority of our fan base come from Mexico, Canada, and within the United States. I think Vegas obviously is incredibly special that they cater to everyone. I think they have something like 150,000 hotel rooms that spam from five star all the way through, and so one of the things that we had to pivot from in the first year where we expected Vegas to be this really, really high end proposition was actually that we needed to cater for all different types of ticket package and hospitality package. So we've learned those differences. We thought that it would be very, very high end and mostly international. It's actually around 80% domestic, but drive in traffic and fly in traffic from other US markets in. Like I said, Canada and Mexico have been significant buyers of the Grand Prix and Vegas.Ilyse Liffreing (12:59):Very cool. I'm very curious what kind of feedback you've gotten so far from those fans, sponsors, broadcasters, anybody watching the sport in Vegas?Emily Prazer (13:09):Well, the sponsors love it because it's something different. Like I said, we put a lot of emphasis on the production. What we were all really surprised about was the quality of the racing. I think it has the most overtakes on the Formula one calendar, so that was something we weren't going to know until you can do simulations, but until you see cars going around the track in the first year, we didn't really acknowledge or understand how great the actual racing would be. So I think that was the biggest surprise around feedback and what the broadcasters and general audience have been quite positive about shifting. The mentality and mindset has been something that we're proud of, but it's all stemming from the confidence we've gained through promoting our own event.Ilyse Liffreing (13:47):When you look at success, what KPIs are you most interested in? Is it ticket sales or,Emily Prazer (13:54):I think it's all around halo effect for the sport ticket sales and revenue is obviously my ultimate goal. I'm the chief commercial officer of Formula One, so I don't think I can sit here and say otherwise, but brand extension and growing the fandom and being engaged, giving another touch point to the US audience when again, I mentioned Liberty bought Formula One in 2017, they were very clear that they had two very strategic objectives. One was growing the sport in the United States, the other was growing the sport in Asia and obviously Asia's taken a little bit longer for obvious reasons with COVID and what have you, but we're starting to see the momentum pick up again there. The US we heavily focused on signing Miami as a starting point as a partnership with the Miami Dolphins, which we're really happy with, proud of as they have shown us how to do it. Seeing how they put their event on before we even put on Vegas meant that we could really take their learnings. But yeah, the expectations are that we continue to grow it, that the production level remains incredibly high and that it's our tempo event in the Formula one calendar.Damian Fowler (14:55):Now, you mentioned the Netflix show Drive to Survive, and obviously there's been a lot of media around the importance of that show. Could you talk a little bit about the significance of that show, how it helps or not inspire marketing strategy?Emily Prazer (15:09):Yeah, it comes back to this always on point that I mentioned before, which is Formula One needs to be accessible for the next generation of fans to truly understand it and the next generation of fans care about the competitive nature of the racing, but they also want to understand the personalities behind the sport, and I think it gave us the opportunity to open up to be able to show who we all are. The technical terminology, the filming that went into that and the movie to be honest, has given us the opportunity to use that content to be able to explain what DRS means or what is the significance of each Grand Prix, what does it actually mean? So these drivers like the NFL, when a player puts on a helmet, it's hard to understand the emotion, but being able to get to know the drivers and the team behind the drivers, which is also incredibly important, has been really helpful in our marketing strategy.(16:01):But what it inspired was how do we talk to the different audience? Like I said before, you can't talk to that audience the same way that you talk to the 75-year-old fan that's been going to Silverstone since its inception. So a lot of it has been about how we change our thoughts around short form content and how we use different platforms. To talk to a different audience in different markets has just meant that we've had to learn how to engage and pivot from just broadcast on a Sunday to every minute of every day coming up with new ideas to talk to the fan base.Damian Fowler (16:34):That's pressure for sure. You also mentioned the different channels, and we do talk about a lot about how live sports is now available across many, many different channels and tech platforms are bidding next to traditional broadcasters. I wonder in the mix of things, and especially when it comes to the show and when you broadcast it, how important has that kind of explosion as it were of channels been?Emily Prazer (17:00):I mean we have been ahead on the curve on that somewhat for we are different. Formula One owns its own broadcast capability. We have an office or a building in the UK in Big and Hill and Kent for those that have been in London, been to Kent around London and it's incredible. We own and operate again the whole thing. So every camera, every fiber optic cable, everything you see at a Grand Prix is being produced by Formula One. We have remote operations at the track that go back to Big and Hill and we have 180 broadcasters globally. So we've always been slightly different to other mainstream sports in that regard because we produce our own show, which is helpful for us around sponsorship and what have you. But generally speaking, I think obviously the world is changing and we've got to make sure we keep up with it.Ilyse Liffreing (17:47):Looking forward, which marketing innovations, there's obviously a lot right now, but ai, contextual, programmatic, what excites you the most? Is there any digital marketing innovations?Emily Prazer (18:02):Yeah, I think AI is something that we are excited but cautious. Again, with the sport that's so technologically advanced, you've got to be thoughtful about how we use it. We also don't want to lock ourselves in one direction or the other. So we're doing a lot of work without Formula One has the most unbelievable roster of tech partners. If you think about Salesforce, AWS, Lenovo globin to name a few, they're going to tell us how to use AI to benefit our sport, not just commercially, but on the tech side. So we are very excited about it, not just from a marketing point of view, but from a just general point of view. How does AI benefit the sport? We're taking a massive amount of time to think about just general activations. I know that sounds kind of immature if you think about Formula One, but how do we bring different activity to the track outside of just races? I'm not sure if either of you saw what we did in Miami with Lego, where Lego built 10 full size cars for the drivers to race Lego cars around the track.Damian Fowler (19:05):I show my son that. That'sEmily Prazer (19:06):So cool. If you think about the content that that created around marketing, that was probably the most viral thing we've done in a very, very long time. So our marketing strategy at the moment is about solidifying the brand equity, making sure that we deliver against our partnership objectives and that we continue to grow our social platforms. I'm not going to say that we're not technically as advanced, but the data capabilities is all quite new to Formula One. Loyalty programs are all quite new to us, so for us, I keep coming back to it, but it's really about figuring out how to engage with the audience and have something to sell them. Again, we're a rights holder that doesn't have tons of assets to sell ourselves. We license a lot out, and so really it's about coming up with these creative ideas to be kind of 10 steps ahead of anyone else.(19:53):And I think we are in a very unique space. We're very lean, which means we can be very nimble. So when we're making a lot of these decisions, it's me going to Stefano who's the CEO of Formula one saying, how do you feel about us trying something like this? And that's again, where we link the Vegas piece together with the broader marketing strategy to continue to keep everyone engaged rather than it just being like a technical marketing play. Obviously we do that day in, day out, but I think for us it's the confidence we've got now to really push the boundaries and be the first to do a lot of different things, whether it be what we're doing in the broadcast around all of the different types of digital advertising and what have you. I think again, if you watch the races, you'll start to see that we are trying and testing new technologies in thatIlyse Liffreing (20:37):Way. And on that note, we talked a little bit before about the timing of the race in Vegas. InEmily Prazer (20:46):Vegas. Yeah.Ilyse Liffreing (20:47):Because it's a new time for you guys thatEmily Prazer (20:49):10:00 PM Yeah, we moved it forward from 10:00 PM to 8:00 PM which is great. I think a lot of people were struggling with how that's local time, right? Local time, yeah. When we first went to Vegas, the idea was that the timing would be in line with the boxing match or the show. So it wasn't done for any other reason than 10 o'clock on a Saturday night in Vegas is when typically you start seeing things happen. The difference being is that the distance or time you need to keep between certain amounts of sessions meant that it created gaps. So if there were delays that 10:00 PM could technically be pushed. And so we had our issues in the first year. We learned from those last year operationally delivered really well, but we still felt that it was slightly too late, hence the 8:00 PM start. So everything has shifted forward. We have F1 Academy this year, which we're really excited about, so that will, I think doors now open at 2:30 PM rather than four. So it means everything will be a lot earlier, but it's all for the show.Damian Fowler (21:48):And presumably you have a kind of global viewership as well, so that all impactsEmily Prazer (21:53):The trends. Yeah, I think it obviously will be beneficial to the east coast market, not so beneficial to the rest of the world, but we still feel good about the viewership numbers and what we're seeing. SoDamian Fowler (22:03):The true fans willEmily Prazer (22:05):Watch you, right? If not next. Exactly. Hands always come through. Exactly.Damian Fowler (22:08):Alright, so we've got some kind of quick fire questions here to wrap this up. So first off, what keeps you up at night in the lead up to this?Emily Prazer (22:16):Everything in the lead up? The lead up. I'm not sleeping at all my first year as A CEO, I think last year it would've been ticket sales. This year it's probably just security and all round operations. So as my role has expanded on the Vegas race particularly, it's just we are opening and closing the track every three hours. It's not like other street races keep their roads closed for up to seven days. We are having to keep it open and close it regularly. You're in one of the busiest roads in North America, so we don't really have much of a choice and we don't want to impact the locals any further. So I think it's just being responsible for the logistics is scary.Damian Fowler (22:58):Wow. I agree. Closing the road down is like mind blowing.Emily Prazer (23:00):Yeah, it is genuinely mind blowing. If you go to Vegas now, you can see that things are still are on their way to being built and it's like, oh wow, this is happening.Ilyse Liffreing (23:10):That is scary. I'm scary for you. What would you say is missing in the US sports sponsorship marketplace that you would love to see happen?Emily Prazer (23:19):Ooh, good question. I haven't thought about the answer to that. That's a hard one. I'm going to have to sit on that one for a minute. Don't worry. Yeah, I mean I can't speak for, I can only really speak for my sport, but I'd love to have the same access to the teams that N-F-L-N-B-A have as the rights holder. We definitely don't get to just sell the team IP as we see fit. We have something in Formula One called the Concord Agreement, which means that we have some restrictions there. But yeah, let me have a think about the broader space. Sorry. I like that answer One hit me.Damian Fowler (23:52):That's a good answer there. We can circle back and do it again if you want, but I like that to be honest. Okay. So which other sports or entertainment brands do you think are nailing their brand positioning right now?Emily Prazer (24:03):I think the NBA and the NFL, they just do it so unbelievably well and they have fandom here. I've never witnessed in the UK you very much see the fandom around a specific team. Here you see genuine fandom around the NFL. And what I love as a Brit in the US obviously is I still can't believe how each of the TV channels cross-promote each other for other games. So you'll be watching Fox and they'll be like, tune into CBS to watch this game. And you're like, oh wow. They really do do it for the greater good of the league. We would obviously it's different. We don't have multiple games in Formula One, but if I think about it in comparison to the Premier League, you really do follow the team. If I'm a Chelsea fan by the way, but I would watch Chelsea, I wouldn't then flip channels to watch Man United in the us.(24:57):I find myself on a Sunday watching three or four games and I'm like, I'm not even your core audience. It has to be something to do with the marketing that it's always there telling me what to do, telling me how to watch it. And I really admire, maybe this is actually the answer to the previous question. I actually admire how good they are at getting in my head because I think about it, I'm like, what games are on a Sunday or what playoffs are happening in the NBA and I go to watch it because it's there. Whereas like I said, premier League, as much as I'm a huge Chelsea fan and grew up with it, you just don't seem to be able to follow it like that.Damian Fowler (25:35):Yeah, that's very interesting. Would you say you were an NFL fan before you came to theEmily Prazer (25:39):Us? No, not at all. Didn't know the rules and now I'm like hardcoreDamian Fowler (25:42):Because of the marketing, I guess.Emily Prazer (25:43):Wow. Must be. They just got in my head.Damian Fowler (25:46):Amazing. Yeah. And that's it for this edition of The Big Impression.Ilyse Liffreing (25:54):This show is produced by Molten Hart. Our theme is by love and caliber, and our associate producer is Sydney Cairns.Damian Fowler (26:01):And remember,Emily Prazer (26:02):We've had to learn how to engage and pivot from just kind of broadcast on a Sunday to every minute of every day coming up with new ideas to talk to the fan base.Damian Fowler (26:13):I'm Damian. Ilyse Liffreing (26:14):And I'm Ilyse.Damian Fowler (26:14):And we'll see you next time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen talk with Dr. Akturk about the potential health risks associated with cannabis use for people living with diabetes. Cannabis use can affect blood glucose management, heart health, and even how someone manages their medications.  Understanding the risks of cannabis use is an important part of managing diabetes safely. Staying informed and having open conversations with your health care team are the best ways to protect your health. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Halis Kaan Akturk, MD, Associate Professor of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

In this inaugural episode of CTSNet's new podcast, The Cardiac Recovery Room, moderator Dr. Daniel Engelman, Medical Director of the Cardiac Surgical Critical Care & Inpatient Services at Baystate Health, Professor of Surgery at the University of Massachusetts Chan Medical School—Baystate, and President of the ERAS Cardiac Society, spoke with Drs. Rakesh Arora, Director of Perioperative and Cardiac Critical Care and Research Director in the Division of Cardiac Surgery at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio, USA, and Michael C. Grant, Associate Professor at Johns Hopkins University School of Medicine in the Department of Anesthesiology and Critical Care Medicine, about cardiac surgery myths.   Chapters 00:54 Are There Myths? 02:49 Applying Non-Cardiac Surgery Data 04:52 Reducing NPO, Diabetes Carb-Load 08:17 Postop, Crystalloid Volume 10:31 Bicarb Usage 12:10 Hematocrit & Hemoglobin 14:53 Bronchoscopy for Early Extubation 18:54 Routine X-Rays 22:19 Lactates 24:48 Sleeplessness & Delirium 31:14 Final Thoughts They discuss important topics such as the rationale for reducing nothing by mouth (NPO) guidelines, NPO after midnight, and the implications of carbohydrate loading for patients with type 1 diabetes. They examine critical issues of volume resuscitation, comparing the use of albumin vs crystalloids, as well as bicarb usage. Additionally, they evaluate hematocrit and hemoglobin levels, questioning whether specific thresholds should be established. The conversation also covers bronchoscopy for early extubation, inline suctioning for a bronchoalveolar lavage (BAL), and the necessity of daily chest x-rays following cardiac surgery. Furthermore, they address topics such as lactates, sleep aids, and delirium.  The Cardiac Recovery Room is the place to hear the conversations colleagues are having after the meetings. Each month, a new episode will be released featuring a leadership panel from the ERAS Cardiac Society.  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Vi har været på arbejde hele aftenen og natten for at give dig det vigtigste fra kommunalvalget. Vært: Adrian Busk. Medvirkende: Christine Cordsen, DRs politiske korrespondent. Hans Peter Geil, tidligere borgmester, Gram og Haderslev, Venstre.

Audible Bleeding Editor and vascular surgery fellow Richa Kalsi (@KalsiMD) is joined by 4th year general surgery resident Joe El Badaoui (@JosephBadaouiMD), JVS editor Dr. Audra Duncan (@ADuncanVasc), and JVS-VS editor Dr. John Curci (@CurciAAA) to discuss two great articles in the JVS family of journals. The first article discusses an extensive experience using cryopreserved arterial allografts for vascular reconstruction after major oncologic surgery. The second article sheds light on nanoplastics in atherosclerotic plaques.  This episode hosts Dr. Sebastian Cifuentes, Dr. Randall DeMartino (@randydemartino), Dr. Pierce Massie, and Dr. Ross Clark, the first and senior authors of these two papers. Articles: Part 1:Ten-year experience using cryopreserved arterial allografts for vascular reconstruction during major oncologic surgery (Drs. Cifuentes & DeMartino) Part 2: Micro- and nanoplastics are elevated in femoral atherosclerotic plaques compared with undiseased arteries (Drs. Clark & Massie) Show Guests  Dr. Sebastian Cifuentes is a first year integrated vascular surgery resident at University of Michigan in Ann Arbor, MI Dr. Randall DeMartino is a Professor of Surgery and the chair of the Division of Vascular and Endovascular Surgery at the Mayo Clinic in Rochester, MN Dr. Pierce Massie is a general surgery resident in his research time at the University of New Mexico School of Medicine in Albuquerque, NM Dr. Ross Clark is an Assistant Professor of Vascular Surgery and Assistant Professor of Cell Biology and Physiology at the University of New Mexico School of Medicine in Albuquerque, NM Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.  

"Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Glazer to the podcast! Edward Glaser, DPM Podiatrist • Foot Biomechanist • Inventor of MASS Posture Theory • Founder & CEO, Sole Supports, Inc. Dr. Ed Glaser holds a doctorate from the New York College of Podiatric Medicine and began his journey with a foundation in mechanical engineering from SUNY Stony Brook.  He spent 13 years in private practice before dedicating his energies to developing a new paradigm in foot biomechanics. Ed is the creator of MASS Posture Theory, which views foot biomechanics through an engineering lens, using an all-axis model based on an individual's ideal gait.  He is also the inventor of Relax, Release, Relief (RRR) — a method of interrupting neurological feedback loops that contribute to chronic pain. As founder and CEO of Sole Supports, Inc., Dr. Glaser has built a reputation for reimagining orthotic design, focusing on calibrated full-arch support to prevent postural collapse and optimize function. Over decades, he has lectured at medical conferences worldwide, published his work (including in the Foot & Ankle Online Journal), and taught his methodology in podiatry and chiropractic programs.

Después de una semana sin F1, comenzamos el último triplete de la temporada con Las Vegas. Desde el Podcast Técnica Fórmula 1, no es que lleguemos locos de contentos a esta pista, más bien todo lo contrario, pero tendremos un fin de semana al uso y el campeonato, lejos de estar resuelto presenta muchas incógnitas. Cómo estamos y qué podría pasar. Norris lidera adecuadamente el Campeonato. Tiene un buen colchón de puntos sobre sus rivales, pero recordemos que el año pasado este fue el peor GP del año para McLaren. Cualquier problema, cualquier fallo de envergadura, cambiará el guion de manera contundente. Esto añade tensión a un fin de semana que, pese al escepticismo hacia el circuito, se presenta cargado de incógnitas y potenciales sorpresas. El análisis técnico del trazado revela un circuito urbano muy particular. Con 6,201 kilómetros, es la segunda pista más larga del campeonato, y también una de las más rápidas. Casi el 80% de la vuelta se recorre a fondo, con rectas extensas – incluyendo la icónica sección por el Strip – y puntos de frenada violentos como la curva 14, donde los coches pasan de 350 km/h a apenas 102 km/h en menos de tres segundos. La mayor incógnita de todas, el ser una pista urbana El mobiliario urbano, las irregularidades propias del tráfico habitual y los residuos de aceite limitan el agarre, haciendo que la evolución de la pista a lo largo del fin de semana sea especialmente significativa. Respecto a los neumáticos, Pirelli vuelve a apostar por la combinación más blanda disponible: C3, C4 y C5. La elección se mantiene por tercer año consecutivo. Sin embargo, en esta ocasión las circunstancias térmicas podrían mejorar ligeramente gracias a que todas las sesiones comenzarán dos horas antes que en la última edición, lo que facilitará el calentamiento de los compuestos. Aun así, el reto de gestión de temperatura seguirá siendo determinante, especialmente en clasificación, donde la vuelta de preparación resultará crucial. Además, Pirelli ha introducido este año mejoras en las propiedades mecánicas de los neumáticos, lo que debería ayudar a reducir una degradación que en 2024 afectó especialmente al compuesto medio. La amenaza del graining y la baza de la estrategia. La decisión de no utilizar un trío aún más blando radica en el riesgo de graining, un fenómeno muy presente desde la primera edición en este circuito y que podría comprometer gravemente el rendimiento de los neumáticos más blandos. El año pasado, la mayoría de pilotos apostaron por salir con medios, reservando dos juegos de los compuestos más duros para una estrategia de dos paradas que permitiera exprimir los neumáticos sin necesidad de gestionarlos en exceso. En el apartado estratégico, Pirelli recuerda que la clave para encontrar la “jugada ganadora” reside en el análisis exhaustivo de datos previos y simulaciones. Antes de cada carrera, la marca italiana proporciona a los equipos escenarios teóricos basados en diferencias de rendimiento entre compuestos, vida útil estimada y degradación histórica. A esto se suma la información acumulada durante la temporada y las variaciones en carga de combustible. Paralelamente, los equipos utilizan métodos más complejos, que incorporan probabilidades de coche de seguridad, tráfico y facilidad de adelantamiento en zonas DRS. Hablando de los frenos. La exigencia del circuito en términos de frenado es media, según Brembo, con un índice de dificultad de 3 sobre 5. A pesar de contar con siete zonas de frenada, los frenos solo se utilizan durante 14,5 segundos por vuelta. Sin embargo, cinco de los puntos de frenado superan los 115 metros, y la curva 14 vuelve a destacar como el mayor desafío tanto para los pilotos como para los sistemas de frenado. La progresiva mejora del agarre durante el fin de semana incrementará también la demanda sobre discos y pastillas, aumentando las temperaturas de funcionamiento. Con toda esta información, aunque el GP de Las Vegas, sobre todo hablando del circuito, no es de los favoritos de los aficionados de raza, las cuestiones que hay sobre la mesa (gestión de las gomas, decisiones estratégicas, evolución de la pista,…) así como la situación tan interesante en la que se encuentra el Campeonato de pilotos, hace que, quizás esta vez, sí que nos guste este Gran Premio. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Goedenmorgen! Today, travel medicine specialists Drs. Paul Pottinger & Chris Sanford answer your travel health questions, including:IV hydration spas are everwhere... are they safe?Do I need to be immunized against diphtheria?Prickly Heat and Disney Vasculitis–What's the difference?What is hepatitis E?Rotten Air BNB with nice hosts… ethics of an honest review?WTF is up with chikungunya on Long Island?How to avoid–and treat–low back pain on long trips?How can I tell if I'm fit enough for an upcoming trip?We hope you enjoy this podcast! If so, please follow us on the socials @germ.and.worm, subscribe to our RSS feed and share with your friends! We would so appreciate your rating and review to help us grow our audience. And, please visit our website: germandworm.com where you can find all our content and send us your questions and travel health anecdotes. Or, just send us an email: germandworm@gmail.com.Our Disclaimer: The Germ and Worm Podcast is designed to inform, inspire, and entertain. However, this podcast does NOT establish a doctor-patient relationship, and it should NOT replace your conversation with a qualified healthcare professional. Please see one before your next adventure. The opinions in this podcast are Dr. Sanford's & Dr. Pottinger's alone, and do not necessarily represent the opinions of the University of Washington or UW Medicine.

Ved du heller ikke, hvem du skal stemme på i dag? Trump sender jægerfly, hangarskib og atomubåd mod Venezuela. Flere partiers hjemmesider har været udsat for cyberangreb. Vært: Adrian Busk. Medvirkende: Kristian Almblad, DRs sydamerikakorrespondent. Roger Buch, Forsker, underviser og kommunalvalgsekspert, DMJX.

‍ ‍Drs. Akshay Thomas and Sarwar Zahid join for a journal club episode discussion of three recent publications:‍ ‍ ‍ ‍Fellow Eye PVD (https://journals.sagepub.com/doi/full/10.1177/24741264251379842)‍ ‍Syfovre versus Izervay (https://journals.sagepub.com/doi/full/10.1177/24741264251379842)‍ ‍Litigation Involving Intravitreal Injections (https://www.ophthalmologyretina.org/article/S2468-6530(25)00439-7/abstract)‍ ‍ ‍ ‍Disclosures: Dr. Sridhar has consulted for Apellis and Astellas in the past 3 years. ‍ ‍

In episode 109, we sit down with Drs. Ian Katz and Shelly Rauvola, co-editors of a groundbreaking special issue in Industrial and Organizational Psychology. Together, we explore how current public policy changes in the United States are reshaping the world of work, from employee well-being and marginalized worker experiences to the future of I-O psychology education and research.Key takeaways include:* How policy changes impact HR practices, training, and organizational functioning* The chilling effect of political climates on academic freedom and research* Why behavioral scientists must engage in policy conversations* How I-O psychology can respond using existing theories and evidence-based practices* A call to action for researchers and practitioners to advocate for worker dignity and evidence-based decision-makingThis episode is essential listening for anyone invested in the future of work, science advocacy, and the role of IO psychology in shaping policy.Find the special issue here: https://www.cambridge.org/core/journals/industrial-and-organizational-psychology/issue/380836BA2B93123CE626AACDCB5DF7DAFind Ian Katz here: https://csh.depaul.edu/faculty-staff/faculty-a-z/Pages/psychology/ian-katz.aspxFind Shelly Rauvola here: https://csh.depaul.edu/faculty-staff/faculty-a-z/Pages/psychology/shelly-rauvola.aspx This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit healthywork.substack.com

In the November 2025 episode of RAPM Focus, ASRA Pain Medicine Past-President and RAPM Editor David Provenzano, MD, converses with Megan Rolfzen, MD, and Karsten Bartels, MD, PhD, MBA, following the July 2025 publication of their original research article, “Post-Surgical Medication, Awareness, Recovery, and Tracking Using a Phone-Based App (SMART-APP): A Randomized Controlled Trial.” In their clinical trial, Drs. Rolfzen, Bartels, et. al., tested the hypothesis that a patient-facing educational smartphone app would permit surgical patients to effectively manage their pain while using fewer opioids after discharge. Dr. Rolfzen is an assistant professor of anesthesiology at the University of Michigan and a scholar in the NIH T90 HEAL PAIN program.  Dr. Bartels is a professor of anesthesiology, psychiatry, and learning health sciences at the University of Michigan and leads a research program focused on perioperative pain and mental health. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on X @RAPMOnline, LinkedIn @Regional Anesthesia & Pain Medicine, Facebook @Regional Anesthesia & Pain Medicine, and Instagram @RAPM_Online.

In this 321st episode I welcome Drs. Saddawi-Konefka, Ehrenfeld and Yu Moutier to the show to discuss how we can reduce barriers to mental health care for physicians and other health care providers, why this is so important, and concrete steps that leaders and institutions can take today. Our Sponsors:* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Factor and use my code accrac50off for a great deal: https://www.factor75.com* Check out Truelearn: https://tinyurl.com/ACCRACTL* Check out Uncommon Goods: https://uncommongoods.com/ACCRACAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

“Send us a Hey Now!”It's an off week before we head to Vegas so this week we decided to take a look at a season that has a few things in common with this season.The 2007 season saw McLaren end up with two number one drivers who battled each other for the title whilst also trying to fend off a driver from another team!Sound familiar?We look at a number of other things that took place that year as there was a LOT of talking points that came up that season.Episode running order as always is...1) News & SocialAll the best bits from both the sports news out there as well as what caught our eye on the various social channels2) Brian's Video Vault        https://www.youtube.com/watch?v=WQiOzFTKIAQ. Unearth Your Greatness | Adrian Newey on the Craft of Racecar Design. Aston Martin Aramco F1 Team. 11 mins. https://www.youtube.com/watch?v=Us0dyphXd4Q. Formula One star Valtteri Bottas earns honourary Aussie title https://www.youtube.com/watch?v=-0Ni12Up0F8. Lando Norris Behind the Scenes at Waldorf Astoria Amsterdam. https://www.youtube.com/watch?v=DqI6bs75v7Q. Working Nine to Drive | Episode 1. https://www.youtube.com/watch?v=15InCiOeH20&t=346s. Cadillac F1 Team First Ever Test! Checo Perez Driving a Ferrari SF-23 at Imola Circuithttps://www.youtube.com/watch?v=rjN0lz0SySw. Every Time the Halo Saved a Drivers Life…. https://www.youtube.com/watch?v=VJuKqOQBDhs. LIVE: Crazy Sao Paulo Grand Prix Drivers' Parade! 3) 2007: A Race OdysseyA Vale's tales style lookback at the 2007 seasonThe two videos we reference:https://youtu.be/zVE6HCHgUuI?si=Wv6tceL53DFJUkgV Crash 300 KPH - Robert Kubica - Grand Prix Canadá - Formula 1 - 2007https://www.youtube.com/watch?v=2wAsVO4YiFU F1 Indy 2007 GP USA Fernando Alonso Vs Lewis Hamilton!4) Las Vegas PreviewIt's going to be a race week again so we preview the race in Vegas.Support the showWe would love you to join our Discord server so use this invite link to join us https://discord.gg/XCyemDdzGB To sign up to our newsletter then follow this link https://dirty-side-digest.beehiiv.com/subscribeIf you would like to sign up for the 100 Seconds of DRS then drop us an email stating your time zone to dirtysideofthetrack@gmail.comAlso please like, follow, and share our content on Threads, X, BlueSky, Facebook, & Instagram, links to which can be found on our website.One last call to arms is that if you do listen along and like us then first of all thanks, but secondly could we ask that you leave a review and a 5 star rating - please & thanks!If you would like to help the Dirty Side promote the show then we are now on Buy me a coffee where 100% of anything we get will get pumped into advertising the show https://www.buymeacoffee.com/dirtysideofthetrackDirty Side of the Track is hosted on Buzzsprout https://www.buzzsprout.com/

Today we give you our conversation with Drs. Jennifer Puig and Lisa Drozdick on the update to the Advanced Clinical Solutions, including the Test of Premorbid Functioning, 2nd Edition, which are scheduled for release sometime in 2026. We previously spoke with Jenn and Lisa about the WMS-5, with the episode released on November 1st.  We have no financial or other relationship with Pearson and The INS neither promotes nor recommends any commercial products or services discussed in this episode. Show notes are available at www.NavNeuro.com/179 _________________ If you'd like to support the show, here are a few easy ways: 1) Get CE credits for listening to select episodes: www.NavNeuro.com/INS  2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes 4) Check out our book Becoming a Neuropsychologist, and leave it an Amazon rating   Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners' own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

Dr. Julie Ann Justo is joined by experts Drs. Krista Gens and Javier A. Villafuerte Gálvez as they dive deep into the gut microbiome and explore the latest therapeutic frontier for C. difficile infections.  From bacteria battles to breakthrough treatments, this one's a must-listen! You can also review the helpful infographic on our website (https://breakpoints-sidp.org/infographics/). This podcast was supported by an unrestricted grant from Nestlé Health Science. References: Helpful review from one of our guest experts: Gens KD, et al. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. J Pharm Pract. 2013 Oct;26(5):498-505. doi: 10.1177/0897190013499527. PMID: 23966282. More modern review: Herbin SR, et al. Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies. J Pharm Pract. 2024 Dec;37(6):1361-1373. doi: 10.1177/08971900241248883. Epub 2024 May 13. PMID: 38739837. Review on designing microbiota based therapies (pre-print only): Ke S, et al. Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection. 2024 May 02. doi: 10.1101/2024.04.30.591969. [FDA Guidance regarding IND requirements for fecal microbiota transplant](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota). 2022 Nov. OpenBiome webpage with resources for hospitals: How to Start an FMT Program. 2025. Peery AF, et al. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024 Mar;166(3):409-434. doi: 10.1053/j.gastro.2024.01.008. PMID: 38395525. Johnson S, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 Sep 7;73(5):755-757. doi: 10.1093/cid/ciab718. PMID: 34492699. Henry Ford's experience getting fecal microbiota products for patients: Abene S. Fecal Microbiota Capsules Improve CDI Access Through Specialty Pharmacy Integration. Contagion Live. 2025 Jul 11. An international view on CDI management: Mendo-Lopez R, et al. Best Practices in the Management of Clostridioides difficile Infection in Developing Nations. Trop Med Infect Dis. 2024 Aug 19;9(8):185. doi: 10.3390/tropicalmed9080185. PMID: 39195623. Review on investigational LBP agents: Monday L, et al. Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details. Infect Drug Resist. 2024 Feb 15;17:623-639. doi: 10.2147/IDR.S419243. PMID: 38375101. More on quorum sensing: Falà AK, et al. Quorum sensing in human gut and food microbiomes: Significance and potential for therapeutic targeting. Front Microbiol. 2022 Nov 25;13:1002185. doi: 10.3389/fmicb.2022.1002185. PMID: 36504831. Economic impacts of CDI pts: Reilly J, et al. Economic impact of multiple recurrent Clostridioides difficile infection in a community teaching hospital. Infect Control Hosp Epidemiol. 2025 Sep 29:1-3. doi: 10.1017/ice.2025.10295. Epub ahead of print. PMID: 41020576.

Dean's Chat hosts, Drs. Jensen and Richey, welcome the American Podiatric Medical Association student representatives from Western University College of Podiatric Medicine. This episode is sponsored by the American Podiatric Medical Association! Jeslyn Dela Vega, Carissa Smith, and Sarah Marzouk, join us to discuss how they discovered podiatric medicine, their shadowing experiences, and things that have surprised them in school. They also discuss things that have inspired them, and a series of "Rapid Fire" questions! They also share "professor shout-outs" and their roles with APMSA! Enjoy this conversation with student leaders! #Podiatry #FootAndAnkle #Residency #MedicalEducation #Surgery #PodiatricMedicine #PreMed #HealthCareCareers #DeansChat

CTL Script/ Top Stories of November 14th Publish Date: November 14th   Pre-Roll: From the Ingles Studio Welcome to the Award-Winning Cherokee Tribune Ledger Podcast  Today is Friday, November 14th and Happy Birthday to Alec John Such I’m Peyton Spurlock and here are the stories Cherokee is talking about, presented by Times Journal Canton hears from residents on proposed 28-home neighborhood Retired Cherokee County firefighter dies after cancer battle Wellstar opens new GI clinic at Cherokee Health Park Plus, Leah McGrath from Ingles Markets on pesticides We’ll have all this and more coming up on the Cherokee Tribune-Ledger Podcast, and if you’re looking for Community news, we encourage you to listen and subscribe!  Commercial: STRAND THEATRE STORY 1: Canton hears from residents on proposed 28-home neighborhood The Canton City Council is set to vote Dec. 4 on a proposal to build a 28-home subdivision on Fate Conn Road, but not without some serious pushback from locals. At a Nov. 6 public hearing, residents raised concerns about traffic, flooding, and the loss of greenspace. Earl Darby didn’t hold back: “We’ve had fatalities on that road... we don’t need more cars until there’s a plan to fix it.” Others echoed worries about stormwater runoff and privacy buffers. The developer, Legacy Design and Development, says they’ll address runoff with a stormwater system, but specifics? Still TBD. STORY 2: Retired Cherokee County firefighter dies after cancer battle Cherokee County Fire and Emergency Services is grieving the loss of retired Lt. Dave Burnaugh, who passed away after a relentless fight with cancer. Burnaugh, who retired in September, was diagnosed in 2022 with a Stage 3 brain tumor and a Stage 1 kidney tumor. Despite the odds, he returned to duty last summer after 10 months, greeted by a hero’s welcome from his CCFES family and beyond. Known for his faith, humility, and unwavering dedication, Burnaugh mentored countless firefighters during his nearly two decades of service. His legacy? It’s one of compassion, leadership, and love. STORY 3: Wellstar opens new GI clinic at Cherokee Health Park Last week, Wellstar Health System and the Cherokee County Chamber of Commerce celebrated a big milestone at Cherokee Health Park—the addition of gastroenterology services. The ribbon-cutting for the new GI Suite took place Nov. 5, though the clinic has been seeing patients since September, with procedures starting in October. “This expansion is all about bringing expert care closer to home,” said Christine Beam, Wellstar’s executive director of health parks. The GI team includes Drs. Inder Tandon, Margaret Morrison, and Nidah Khakoo, offering care for everything from liver issues to digestive disorders. Cherokee Health Park just keeps growing—one-stop care, right in Holly Springs. We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info.    We’ll be right back. Break: Ingles Markets 2 STORY 5: Woodstock hosting two recycling events on Saturday  Woodstock is hosting not one, but two recycling events this Saturday, Nov. 15, from 9 a.m. to 1 p.m. at Woodstock City Church (150 Ridgewalk Parkway). It’s a chance to declutter and do some good for the planet—win-win, right? The “’Tis the Season to Be Green!” event is open to everyone and will take electronics, cardboard, batteries, eyeglasses, and more. Plus, free paper shredding (up to 10 boxes). They’re also collecting gently used items for Children’s Healthcare of Atlanta. Meanwhile, Woodstock residents can drop off hazardous waste—paint, chemicals, Styrofoam—at a separate area. Registration required at LiveThrive.org/Woodstock. And now here is Leah McGrath from Ingles Markets on pesticides Commercial: We’ll have closing comments after this.   COMMERCIAL: STRAND THEATRE   SIGN OFF –   Thanks again for hanging out with us on today’s Cherokee Tribune Ledger Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.tribuneledgernews.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com Strand Marietta – Earl and Rachel Smith Strand Theatre See omnystudio.com/listener for privacy information.

Today on the Producer's Choice Show we look back at the history of Veterans Day and look forward to a future of supporting vets in education. Host Producer Jakob welcomes guests Drs. Tim Slekar and Johnny Lupinacci to discuss the contributions veterans make on campus, the strengths of our system in helping veterans transition into civilian life through education, and the areas with room for improvement. It's a grateful, patriotic education discussion on THIS exciting episode of the Producer's Choice Show! The Producer's Choice Show with Producer Jakob is part of BustED Pencils: Fully Leaded Education Talk which is part of Civic Media. Subscribe to the podcast to be sure not to miss out on a single episode! Go to bustedpencils.com for swag, all of our episodes, and for information on partnering with us! For information on all of the programming across the Civic Media network, head over to https://civicmedia.us/shows. Join the conversation by calling or texting us at 608-557-8577 to leave a message! Guests: Dr. Tim Slekar, Dr. Johnny Lupinacci

Er Lars Rebien magtfuldkommen, når han nu vil stå i spidsen for både bestyrelsen og fonden? Der er korruption og bestikkelse i den ukrainske regering, og folk er rasende. En 25-årig tysker, som bliver kaldt klimaskeptikernes Greta Thunberg har søgt asyl i USA. Vært: Amalie Schroll Munk. Medvirkende: Casper Schrøder, DRs økonomikorrespondent. Mads Jedzini, Phd.-studerende ved Københavns Universitet og Tænketanken Europa.

In this call to action, Drs. Robert Mazzoli, Stuart Seiff, and Jon Perlstein share the scope of issues surrounding ophthalmic trauma care in the United States and a roadmap for improving it, including how we can translate experiences from the military into our own set of Damage Control Ophthalmology (DCO) guidelines. Referenced article: A Call to Action and Roadmap for Improving Emergency Treatment of Ophthalmic Trauma in the United States For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Harry Sutherland speaks with three medical educators about their involvement in national organizations- Drs. Jaffar Khan, Erica Schuyler, and Jeff Dewey. They review the ways one can become involved and why they value their involvement in national organizations including the ACGME, ABPN, AAN, ANA, AALN, and more!

Drs. Mabry and Lee talk with Kim Mayberry from Cookeville Regional Medical Center in recognition of American Diabetes Awareness Month. Kim explains the differences between Type 1 and Type 2 diabetes and discusses who is most at risk, including those with pre-diabetes. She shares insight on early symptoms and non-controllable risk factors, as well as local programs and resources available for diabetic patients in the Upper Cumberland region. Listen To The Local Matters Podcast Today! News Talk 94.1

In this episode, Drs. Milt Lowder and Gabriela Caviedes unpack why stress isn't always the enemy; it's often a signal for growth. They explore how to reframe your relationship with pressure and use it to fuel focus, motivation, and performance readiness. Drawing from both psychology and physiology, they explain what happens in your body under stress and share practical tools to manage it more effectively. Learn how to turn pressure into an advantage rather than a threat.

Drs. Nick Strasser and Pam Luk chat with 2025 AOFAS Legacy Pillar Dr. Roger A Mann. Drs. Keith Wapner and Michael Coughlin join the discussion.  For additional educational resources, visit AOFAS.org

Welcome to the Leading Edge in Emotionally Focused Therapy, hosted by Drs. James Hawkins, Ph.D., LPC, and Ryan Rana, Ph.D., LMFT, LPC—Renowned ICEEFT Therapists, Supervisors, and Trainers. We're thrilled to have you with us. We believe this podcast, a valuable resource, will empower you to push the boundaries in your work, helping individuals and couples connect more deeply with themselves and each other. Here's an engaging show description: "Yellow Lights in Love: Navigating Hesitation and Misattunement in Couples Therapy" In this revealing episode of the Leading Edge in Emotionally Focused Therapy, Drs. James Hawkins and Ryan Rana dive deep into the subtle art of recognizing and transforming "yellow light" moments in couples therapy. Learn how seemingly supportive responses can actually reinforce disconnection in relationships, and discover techniques to help partners truly hear and validate each other's deepest vulnerabilities. Key Points: - Understanding "yellow lights" in EFT: Moments of partial openness or hesitation - The critical difference between reassuring and truly being present with a partner's emotions - How self-regulation and co-regulation work together in healing relationships - Practical strategies for therapists to guide couples from disconnection to genuine emotional attunement Whether you're a therapist, counselor, or simply interested in relationship dynamics, this episode offers profound insights into helping couples create deeper, more authentic connections. To support our mission and help us continue producing impactful content, your financial contributions via Venmo (@leftpodcast) are greatly appreciated. They play a significant role in keeping this valuable resource available and are a testament to your commitment to our cause. We aim to equip therapists with practical tools and encouragement for addressing relational distress. We're also excited to be part of the team behind Success in Vulnerability (SV)—your premier online education platform. SV offers innovative instruction to enhance your therapeutic effectiveness through exclusive modules and in-depth clinical examples.  Stay connected with us: Facebook: Follow our page @pushtheleadingedge Ryan: Follow @ryanranaprofessionaltraining on Facebook and visit his website James: Follow @dochawklpc on Facebook and Instagram, or visit his website at dochawklpc.com George Faller: Visit georgefaller.com If you like the concepts discussed on this podcast you can explore our online training program, Success in Vulnerability (SV). Thank you for being part of our community. Let's push the leading edge together!

If you're a physician with at least 5 years of experience looking for a flexible, non-clinical, part-time medical-legal consulting role… ...Dr. Armin Feldman's Medical Legal Coaching program will guarantee to add $100K in additional income within 12 months without doing any expert witness work. Any doctor in any specialty can do this work. And if you don't reach that number, he'll work with you for free until you do, guaranteed. How can he make such a bold claim? It's simple, he gets results…  Dr. David exceeded his clinical income without sacrificing time in his full-time position. Dr. Anke retired from her practice while generating the same monthly consulting income.  And Dr. Elliott added meaningful consulting work without lowering his clinical income or job satisfaction. So, if you're a physician with 5+ years of experience and you want to find out exactly how to add $100K in additional consulting income in just 12 months, go to arminfeldman.com.                                                          =============== This podcast is sponsored by the Physician Executive MBA Program at the University of Tennessee Knoxville's Haslam College of Business. Thinking about a nonclinical career path? In just one year, our physician-only MBA gives you the business and leadership skills to pivot, whether into administration, consulting, entrepreneurship, or beyond. Join a nationwide network of over 1,000 physician leaders. Learn more at nonclincicalphysicians.com/physicianmba.                                                          =============== Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== In this classic episode from 2022, Drs. Lev Grinman and Daniel Cousin share how they built Doctors for Providers, a nationwide network that connects physicians with nurse practitioners and PAs seeking collaborative partnerships. What began as a simple response to constant requests from advanced practice providers has become a streamlined system that helps both sides work more efficiently and safely. Dr. Grinman, a neurologist and sleep specialist, and Dr. Cousin, a radiologist, explain how they identified a hidden demand in healthcare and turned it into a viable business model. They describe how the service works, why it offers physicians flexible nonclinical income, and what they've learned about entrepreneurship along the way from testing ideas and bootstrapping growth to balancing compliance and trust. Their story reveals how spotting a small but widespread problem can evolve into a scalable company and how physicians can leverage their expertise beyond the clinic to build real solutions for the medical community. You'll find links mentioned in the episode at nonclinicalphysicians.com/part-time-remote-medical-director

Bryan Gee is back with the November edition of the V Podcast, and as we get ready to return to Fabric for our annual knees-up, here's something to get you firmly in the mood. This month's episode is stacked with dubwise flavours, soulful steppers, and heavyweight VIPs – featuring new heat from Makoto, L-Side, Command Strange, DJ Die, Crystal Clear, and Alibi, plus vocal pressure from Riya, Inja, DRS, MC GQ, and MC Enamie. Expect big remixes from Business As Usual, Jumpin Jack Frost, Need For Mirrors, and Paul T and Edward Oberon – plus unreleased dubs, cheeky bootlegs, and a few classics from the vault. 01. Riya and Melinki – Only Way We Know 02. MC Fats and Inja – Digital Sync 03. Command Strange and T.R.A.C. – Vasness 04. FD and Fox – Trife Life 05. Makoto – Feels Like Heaven 06. Makoto – How I Do It 07. Makoto and Deizim – Look of Love 08. Carlito – Time 09. DJ Die – New Way 10. Sl8r and Metrodone – Crabs 11. L-Side – Making It Last 12. L-Side – Sooperman 13. L-Side – Don't Ever Wonder (Bootleg) 14. DJ SS – Rollers Music 15. Dawn Penn – No No No (Business As Usual Remix) 16. Voltage, Hurrian and Kenny Ken – Untitled 17. Masicka – Whites (Jumpin Jack Frost Remix) 18. Eccleton Jarrett and Hurrian – Turn on the Heat 19. Think Tonk and DRS – You the Toppa Top 20. Jimi Polo – Better Days (Paul T and Edward Oberon Remix) 21. Mampi Swift – Soul Brother 22. DJ Krust – Hopscotch 23. Roni Size – 26 Bass 24. Jagged Edge – Rock Baby 25. DJ Die – Autumn 26. DJ Die – Sling Shot 27. Need For Mirrors – Tidal Wavey (Remix) 28. Command Strange and Freddy B – Electric 29. Paul T and Edward Oberon feat. MC Moose – Future Style 30. Alibi and Carasel – Slap It Down 31. Alibi – Original Style 32. Alibi – Sequence (Workforce Remix) 33. Brodie, Paul T and Edward Oberon feat. MC Enamie – Mash Up the System 34. Crystal Clear – All I Need 35. Riya and Crystal Clear – Overlook 36. L-Side – Look In Ah Mi Face 37. L-Side and MC GQ – Deep in the Jungle 38. Alibi – Sanctioned 39. L-Side – Slow Down 40. L-Side – Bad That 41. Level 2 – Come Selector 42. L-Side – No Stress 43. Cloud Lord – Ghost Train (VIP) 44. Calyx – Forever

Dr. Gerard Slobogean chats with Drs. Ken Egol and Matthew Kingery about the findings of the Comparison of Bracing with Coaptation Splinting for the initial treatment of acute humeral shaft fractures in the first part of the episode. In the second part of the episode, Dr. Slobogean speaks with Prof. Ben Ollivere about the Operative Rib Fixation RCT results.  Live from the 2025 OTA Annual Meeting.

“Send us a Hey Now!”We went back racing after an off week last week and it was a return to Brazil for the race at Interlagos.The race weekend was also a sprint weekend so we had extra competitive action at a track we love here on the Dirty Side.The flow will be...1) News & SocialAll the best bits from both the sports news out there as well as what caught our eye on the various social channels2) Brian's Video Vault    https://www.youtube.com/watch?v=uZVCOuONHRU&t=234s. 28 Times Drivers Made Breathtaking Saves! Formula 1 channel. 10 mins. This was fine. Beginning was great, then kinda meh for the end..https://www.youtube.com/watch?v=gerjec5EhmA. Can an F1 Driver play the guitar? Visa Cash App RB F1 Team. Liked this way too much.https://www.youtube.com/watch?v=OznUbl1FTwQ. Lando Norris makes a one-of-a-kind burger at Michelin-starred restaurant | Hilton channel. 11 mins. Way too long. Good idea, but could have been much shorter. Chef has a lot of patience for Lando.https://www.youtube.com/watch?v=tjL2fbHBjuI&pp=0gcJCQMKAYcqIYzv. Can F1 Drivers Guess The Circuit From Just The Steering Wheel? Formula 1 channel. 7 mins. WAY TOO HARD. holy cow this was difficult.3) Brazil GP ReviewPractice, Sprint Qualy, Sprint, Qualy, and raceKing of the Pits vs The PitsPitlane PaulCasino Games updateWDC & WCC updatesFantasy UpdateSupport the showWe would love you to join our Discord server so use this invite link to join us https://discord.gg/XCyemDdzGB To sign up to our newsletter then follow this link https://dirty-side-digest.beehiiv.com/subscribeIf you would like to sign up for the 100 Seconds of DRS then drop us an email stating your time zone to dirtysideofthetrack@gmail.comAlso please like, follow, and share our content on Threads, X, BlueSky, Facebook, & Instagram, links to which can be found on our website.One last call to arms is that if you do listen along and like us then first of all thanks, but secondly could we ask that you leave a review and a 5 star rating - please & thanks!If you would like to help the Dirty Side promote the show then we are now on Buy me a coffee where 100% of anything we get will get pumped into advertising the show https://www.buymeacoffee.com/dirtysideofthetrackDirty Side of the Track is hosted on Buzzsprout https://www.buzzsprout.com/

Pediatric trauma hits differently—both emotionally and clinically. In this Big T Trauma episode (2 of 2), Drs. Teddy Puzio, Charles Cox, and Tyler Simpson join Dr. Patrick Georgoff to break down real-world pediatric trauma cases. They explore how mechanism predicts injury, when imaging helps (and when it harms), and the nuances of recognizing non-accidental trauma. Packed with practical takeaways and memorable teaching points, this episode will sharpen your instincts for the next injured child you treat. PECARN Pediatric Imaging Guidelines: https://emscimprovement.center/education-and-resources/peak/multisystem-trauma/imaging/ This episode of Big T Trauma was sponsored by Teleflex, a global provider of medical devices. Learn more at teleflex.com and at the Teleflex Trauma and Emergency Medicine LinkedIn page. BIG T Trauma Series: https://app.behindtheknife.org/podcast-series/big-t-trauma Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Dr. Annette Bosworth, known to many as "Dr. Boz," is a physician, author, and educator leading the charge in metabolic health and the science of ketosis. With over two decades of medical experience, she's helped thousands reclaim their health through lifestyle and nutrition—using the power of ketones to reverse chronic disease, sharpen mental clarity, and boost longevity. A best-selling author and sought-after speaker, Dr. Boz brings a rare mix of medical insight, real-world results, and contagious enthusiasm for helping people transform their lives from the inside out. In this episode, Drs. Tro, Brian, and Annette talk about… (00:00) Intro (02:13) The origin story of "Dr. Boz" (17:39) The #1 factor for sustainable sobriety (23:02) Why Drs. Brian, Tro, and Annette started posting on social media about the connection between physical health and social fulfillment (29:49) Medicating patients versus educating and empowering them (46:04) GLP-1 drugs and ketosis (01:03:28) Microbiome, metabolic health markers, and satiety (01:11:58) Faith, community, and holistic health For more information, please see the links below. Thank you for listening!   Links:   Please consider supporting us on Patreon: https://www.lowcarbmd.com/   Dr. Annette Bosworth: Website: https://bozmd.com/ X: https://x.com/AnnetteBosworth IG: https://www.instagram.com/drboz_annettebosworthmd/ YouTube: https://www.youtube.com/@DoctorBoz   Dr. Brian Lenzkes:  Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author   Dr. Tro Kalayjian:  Website: https://www.doctortro.com/ Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/   Toward Health App Join a growing community of individuals who are improving their metabolic health; together.  Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more.    Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888  Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://doctortro.com/community/ 

Drs. Kat Talcott and Sarwar Zahid join to discuss the December 2025 edition of Retinal Physician, including an overview of TKIs for retinal disease, the fluorinated gas and sustainability question, best practices for research clinical trial sites, and fellowship selection advice.

What is colic, and why is it amongst a horse owner's greatest fears and a veterinarian's most significant challenges? Hear from renowned equine surgeons and colic experts, Drs. Diana Hassel and Liara Gonzalez, and learn how novelresearch, evolving diagnostics, new treatments and a firmer grasp on prevention are affording horses a better chance at survival and recovery than ever before.

Dr. Jack Wolfson, known as “The Paleo Cardiologist,” joins hosts Drs. Tim & May Hindmarsh on the BS Free MD podcast to discuss his pivot from traditional hospital-based cardiology into a holistic, cause-based model of heart health. He shares how his personal and professional experiences led him to challenge the status quo—shifting focus from symptomatic treatment (eg. stents, statins) to underlying causes such as diet, toxins, lifestyle and stress. The conversation explores how a paleo-inspired, whole-food nutrition model, combined with environmental awareness and lifestyle changes, can meaningfully transform cardiovascular risk and patient outcomes.ABOUT THE GUESTDr. Jack Wolfson, DO, FACC, is a board-certified cardiologist, bestselling author of The Paleo Cardiologist: The Natural Way to Heart Health, and founder of Natural Heart Doctor, a holistic cardiology practice based in Arizona. After years in traditional hospital cardiology, he transitioned to a root-cause approach emphasizing nutrition, toxin reduction, and lifestyle medicine. Dr. Wolfson has been featured on CNN, Fox News, NBC, and The Dr. Oz Show, and he continues to educate the public on preventing cardiovascular disease through natural, science-backed methods.Website: https://naturalheartdoctor.comInstagram: @drjackwolfsonGET SOCIAL WITH US!

Pediatric trauma hits differently—both emotionally and clinically. In this Big T Trauma episode (1 of 2), Drs. Teddy Puzio, Charles Cox, and Bhupaul Ramsuchit join Dr. Patrick Georgoff to break down real-world pediatric trauma cases that highlight the ABCs, airway pitfalls, and the art of staying one step ahead when things go sideways. From weight-based dosing and needle cricothyrotomy, to recognizing subtle signs of shock, this one's packed with practical pearls you can use on your next pediatric activation. UT Houston Pediatric MTP: https://med.uth.edu/surgery/pedimtp/ This episode of Big T Trauma was sponsored by Teleflex, a global provider of medical devices. Learn more at teleflex.com and at the Teleflex Trauma and Emergency Medicine LinkedIn page. BIG T Trauma Series: https://app.behindtheknife.org/podcast-series/big-t-trauma Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US